US2022062425A1PendingUtilityA1

Liponucleotide-based therapy for copd

Assignee: OHIO STATE INNOVATION FOUNDATIONPriority: Jun 27, 2017Filed: Sep 10, 2021Published: Mar 3, 2022
Est. expiryJun 27, 2037(~10.9 yrs left)· nominal 20-yr term from priority
Inventors:Ian Davis
A61K 47/543A61K 31/66A61P 11/00
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions and method are therefore disclosed for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF). In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol in a pharmaceutically acceptable carrier for use in treating COPD and/or PF.

Claims

exact text as granted — not AI-modified
1 . A method for treating chronic obstructive pulmonary disease (COPD) and/or pulmonary fibrosis (PF) in a subject, comprising administering to the subject an effective amount of a composition comprising one or more cytidine diphosphate (CDP)-conjugated precursors. 
     
     
         2 . The method of  claim 1 , wherein CDP-conjugated phospholipid precursors are selected from the group consisting of CDP-choline (CDP-CHO), CDP-ethanolamine (CDP-ETH), CDP-diacylglycerol (CDP-DAG), and combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the composition comprises two or more CDP-conjugated phospholipid precursors. 
     
     
         4 . The method of  claim 3 , wherein the composition comprises CDP-CHO and CDP-DAG. 
     
     
         5 . The method of  claim 3 , wherein the composition comprises CDP-CHO and CDP-ETH. 
     
     
         6 . The method of  claim 4 , wherein the CDP-CHO and CDP-DAG or CDP-CHO and CDP-ETH are present in equal concentrations. 
     
     
         7 . The method of  claim 3 , wherein the composition comprises CDP-CHO, CDP-ETH, and CDP-DAG. 
     
     
         8 . The method of  claim 7 , wherein the CDP-CHO, CDP-ETH, and CDP-DAG are present in equal concentrations. 
     
     
         9 . The method of  claim 3 , wherein the CDP-conjugated phospholipid precursors are collectively present at a concentration of at least 0.1 ng per kg of body weight. 
     
     
         10 . The method of  claim 1 , wherein the CDP-conjugated phospholipid precursors comprise one or more chemical modification selected from the group consisting of methylation, esterification, amidation, nitration, nitrosylation, oxidation, sulfation, acetylation, alcoholysis, acidolysis, biotinylation, and fluorophore conjugation.

Join the waitlist — get patent alerts

Track US2022062425A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.